Drug ‘rebate walls’ should be dismantled by the FTC’s antitrust arm
(By David Balto for STAT) While policymakers are giving considerable attention to escalating drug prices and ways to rein them
Read More
Part D/Prescription Drugs
Before Starting A Statin, Talk It Over With Your Doctor
(By Richard Harris for NPR) A study published Monday is pushing back against the notion that up to 40 percent
Read MoreGovernment Investigation Finds Flaws In the FDA’s Orphan Drug Program
(By Sarah Jane Tribble and Sydney Lupkin for Kaiser Health News) The Food and Drug Administration has failed to ensure
Read MoreIntensity, duration of drug shortages are spiking, FDA says
(By Alia Paavola for Becker’s Hospital Review) The FDA is not only seeing an increased incidence of drug shortages, there’s
Read More‘A loss for the rest of us’: An FDA approval is a boon for a drug maker, but could come at a major cost for patients
(By Meghana Keshavan for STAT) Vickie Moored can walk again. Her words don’t slur, her vision isn’t blurred, and she
Read MoreThe long-delayed 340B final rule is out
The rule for the 340B drug discount program, which would set price ceilings and monetary penalties, will begin of next
Read MoreMedicare Part D costs and deductibles for 2019
Do you know what is covered under Medicare Part D? Did you know that private companies that offer Part D
Read MoreDemocrats Taking Key Leadership Jobs Have Pocketed Millions From Pharma
(By Emmarie Huetteman for Kaiser Health News) Three of the lawmakers who will lead the House next year as Congress
Read MoreGetting out of the Medicare drug doughnut hole faster
The new law that bans “gag clauses”, which had prevented pharmacist in some states from letting customers know about a
Read MoreFDA promised a ‘lower-cost option’ to EpiPen, but the price isn’t any lower
(By Ed Silverman for STAT) File this under “When is a bargain not really a bargain?” Three months ago, the
Read More